Compare Ascendis Pharma A/S (ASND) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Prospect Capital Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Prospect Capital Corporation trades at $2.25 (market cap $1.13B). The key difference: Ascendis Pharma A/S is far larger — about 15.7× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 22.17% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PSEC | |
|---|---|---|
Market Cap | $17.74B | $1.13B |
Sector | Health | Financials |
52-Week High | $277.18 | $3.47 |
52-Week Low | $163.32 | $2.15 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 22.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
PSEC trades at $2.26, up 2.26% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.38 and has beaten EPS estimates for three consecutive quarters. Recent news includes a new investment in ShipOffers and the sale of Valley Electric generating $328 million. Dividend payments continue at $0.04-$0.05 monthly, supporting income appeal despite negative revenue and net income in 2025.
Outlook remains cautious due to persistent negative profitability and revenue volatility, though deep discount to NAV and high yield may attract income investors. Key risks include declining NAV, portfolio quality concerns, and analyst skepticism. Upside depends on stabilization of investment income and successful execution of senior lending strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
